For release: 17 May 2018
Circular re Proposed Disposal
Genedrive plc ("the Company")
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, confirms that the circular to shareholders convening a General Meeting for 4 June 2018 in connection with the proposed disposal of the Company's contract research and pharmacogenomics divisions has been posted to shareholders.
Copies of the circular may also be found on the Company's website (www.genedriveplc.com)
- Ends -
For further details please contact:
genedrive plc |
+44 (0)161 989 0245 |
David Budd: CEO |
|
Matthew Fowler: CFO |
|
|
|
Peel Hunt LLP |
|
James Steel |
+44 (0)207 418 8900 |
Oliver Jackson |
|
|
|
Consilium Strategic Communications |
+44 (0)203 709 5700 |
Chris Gardner |
|
Matthew Neal |
|
Laura Thornton |
|
[email protected] |
|
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF assay has been launched in India and a Genedrive® HCV test has received CE-IVD Certification and has been launched in Africa. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and Asia Pacific regions.
Further details can be found at: www.genedriveplc.com and www.genedrive.com
